Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Worg Pharma Raises $152 Million for Allergy and Autoimmune Immunotherapies

publication date: Jul 3, 2023

Worg Pharmaceutical of Shanghai closed a $152 million Series C round to advance its portfolio of novel immunotherapies aimed at allergic and autoimmune diseases along with other indications that target unmet medical needs. The company has two platforms: the PCFiT allergy platform, and the Apitopes platform for autoimmune diseases. In 2020, Worg bought Biomay, an Austrian company, acquiring its PCFiT platform. In 2021, Worg bought Apitopes, a Belgium company with its Apitopes platform candidates. The PCFit platform includes a Phase II candidate for grass pollen and four other allergy therapies. The Apitope platform consists of five assets, three of which have started clinical trials. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital